



Recent Progress in Tuberculosis Vaccine Development

Guest Editor:

Dr. Sunhee Lee

Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA

Deadline for manuscript submissions:

closed (31 May 2022)

Message from the Guest Editor

Mycobacterium tuberculosis (Mtb), the causative agent of TB, kills more people worldwide than any infectious pathogen. The development of new vaccines capable of preventing Mtb infection, including multidrug-resistant tuberculosis, is an essential component of the strategy to combat the TB epidemic.

This recent positive clinical trial data bestow encouraging evidence and represent a critical milestone in global efforts to develop a novel efficacious TB vaccine.

This Special Issue, “TB Vaccine Development”, will present and update the scientific efforts to replace or potentiate BCG in infants and to develop new TB vaccines for adolescents and adults. We welcome submission of manuscripts that investigate: TB vaccine development, strategies to diversify vaccine platforms, new animal models for TB vaccines, reliable models to predict human protection, immunological correlation of protection, limitations in BCG immunity, and breakthrough findings in the basic immunology of Mtb infection to investigate possible targets of vaccine development. We also encourage submissions of manuscripts that explore novel antigens, adjuvant formulations, and routes of vaccination.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com